Officials Visit Shenzhen True Flavor Biotech for Industry Research

Aug.08.2022
Officials Visit Shenzhen True Flavor Biotech for Industry Research
Shenzhen officials visit Shenzhen Zhenwei Bioscience to discuss their development plans and commend their innovative progress.

On August 4th, a delegation led by Cai Ying, Secretary of the Guangming District Committee in Shenzhen, including Shen Huaxin and Zhang Feng, both members of the District Committee, visited Shenzhen Truly Bio-Tech Co., Ltd. They were accompanied by Peng Hua, Deputy Director of the District Committee and Government Office, Lin Shuping, Director of the District Industrial and Information Bureau, Liu Kun, Secretary of the Yutang Street Party Working Committee, Liu Li, Deputy Director of the District Investment Promotion Service Center, and Zeng Peisheng, Deputy Director of the Guangming District Tobacco Monopoly Bureau. The general manager of Truly Bio-Tech, Zou Yang, and other members of management welcomed and hosted the delegation.


A research team conducted a site visit to the offices of Truly Flavored Biotech and received a detailed explanation from the company's leader on various aspects of the company's functional centers, including the introduction of top research equipment, the standardization of process systems, the improvement of talent, and the upgrading of industry intelligence. The team also observed the operation of the Aerosol Technology Research Institute, the pharmaceutical-grade GMP cleanroom, the quality control center, and the fragrance development center, gaining a thorough understanding of the current state of technology personnel, hardware and software facilities, and product development progress. The team engaged in in-depth discussions with staff members and gained a comprehensive understanding of the processes involved in raw material selection, quality testing, and new product research and development. The team fully recognized Truly Flavored Biotech's efforts to "promote innovation-led industry and drive development with scientific research" as a benchmark, a growth booster, and a long-term strategy.


After the visit, a symposium was held under the chairmanship of the Huanxin Executive Committee of the research group.


During the symposium, Secretary Cai Ying fully recognized the work of Zhenwei Biology. She pointed out that as a leading company in the electronic atomized liquid industry, Zhenwei Biology not only has a strong development momentum, but also actively undertakes corporate social responsibility. The company is also forward-thinking in research and innovation, market judgment, and new enterprise layout. At the same time, Secretary Cai Ying expressed deep concern for the company's future development plan. She hopes that Zhenwei Biology will further improve its industrial layout, seize opportunities for further development and expansion, and integrate into the overall development of the Guangming Science City. Meanwhile, the government and various departments of Guangming District will continue to implement pro-enterprise and supportive policies, providing top-notch services and quality space for long-term development and stability of enterprises. The government aims to maintain the vitality of the market, job security, and the welfare of the people in promoting the steady and progressive development of the local economy.


During the meeting, the research team listened to a report from Mr. Zou Yang, the General Manager of Zhenwei Biotech, on the progress and achievements of the company's phase work and the strategic planning for future development. Mr. Zou focused on the current national policies for the electronic atomized liquid industry, Zhenwei's development of new products in compliance with national standards, and the company's economic growth in the first half of the year. He stated that with the help of preferential policies from the government and various departments in Guangming District, Zhenwei Biotech's economic growth has been rapidly increasing since the first half of 2022. Furthermore, in order to better implement industry policy requirements, Zhenwei Biotech established the Zhenwei Biotech (Yunnan) Research Institute immediately after obtaining the tobacco monopoly production license, and is fully engaged in the research of tobacco-flavored atomized products. Zhenwei Biotech hopes to cooperate with the industry's upstream and downstream industries to create electronic atomized products with international influence.


The General Manager, Zou Yang, also stated that Zhenwei Biology will establish itself in Guangming, adhere to the real economy, persist in innovation, elevate its standards, strive to improve the company's efficiency and size, and firmly uphold the industry mission of "being a role model, setting an example, and leading the way." With a foundation in the electronic atomization liquid industry, they will develop in multiple modes, channels, and diversify cooperation, continuously improve market confidence with new development and achievements, make greater contributions to socio-economic development, and also hope that Zhenwei Biology will rely on its strong scientific research capabilities to make a positive contribution to the economic development of Guangming district.


The visit by district leaders is a strong recognition of the achievements in our company's development. In the future, Zhenwei Biological will proactively embrace regulation, adhere to industry policy requirements and government calls, increase research and development investment, and persist in pursuing high-quality development. We will contribute to the economic development of Guangming District and create a win-win outcome.


This article contains excerpts or reprints from third-party sources whose copyrights belong to the original media and authors. If there is any infringement, please contact us for deletion. Any individual or organization that wants to reprint this content should contact the author and refrain from direct reposting.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | VELO Launches Tomorrowland Limited Edition 2026 as Festival IP Enters Nicotine Pouch Packaging
Product | VELO Launches Tomorrowland Limited Edition 2026 as Festival IP Enters Nicotine Pouch Packaging
BAT’s nicotine pouch brand VELO has introduced the Tomorrowland Limited Edition 2026. Public retail-channel information shows the product has appeared across multiple European online platforms, while Haypp UK has listed related SKUs with a “Coming soon” status. The packaging carries the wording “Official Tomorrowland Partner,” indicating that the collection is part of VELO’s official collaboration with the electronic music festival brand.
Jul.02
Sweden Becomes First EU Country to Reach Smoke-Free Status as Daily Smoking Falls to 4.8%
Sweden Becomes First EU Country to Reach Smoke-Free Status as Daily Smoking Falls to 4.8%
According to the latest CAN report and multiple media reports, Sweden’s daily smoking rate fell to 4.8% in 2025, below the commonly used 5% smoke-free threshold, making it the first EU country to reach that benchmark.
News
Jun.05
 Product | ASDF Chroma extends retro cassette visual language with lighting-focused pod design
Product | ASDF Chroma extends retro cassette visual language with lighting-focused pod design
2Firsts noted that ASDF has displayed Chroma on its official website. Public information shows that Chroma is a closed-pod device equipped with an 800mAh battery, switchable RGB lights, haptic feedback and Normal/Boost power modes. It uses a 2ml OSTRO cartridge with 2% nicotine strength. Public information also shows that ASDF has a Malaysian brand background and has previously drawn industry attention for the “retro cassette” visual language used in its Vapetape series.
May.26
Malaysia Police Plan Saliva Tests at Roadblocks to Detect Synthetic Drugs Mixed Into Vape Liquids
Malaysia Police Plan Saliva Tests at Roadblocks to Detect Synthetic Drugs Mixed Into Vape Liquids
Malaysian police plan to use saliva test kits at roadblocks to detect drivers using synthetic liquid drugs marketed as “Piu Piu” and “Magic Mushroom,” substances that authorities say are mixed into vape liquids and inhaled through e-cigarette devices, raising road-safety concerns and adding pressure on vape regulation.
Jun.29
 BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
British American Tobacco’s London-listed shares rose 13.99% last week, as investors focused on the U.S. Food and Drug Administration’s recent authorization of flavored Glas e-cigarette products, the dismissal of a U.S. sanctions-related criminal case against BAT, and the company’s previously announced share buyback plan and newer nicotine business performance.
BAT
May.18
EU Launches Online Feedback as TPD Revision Enters New Milestone
EU Launches Online Feedback as TPD Revision Enters New Milestone
The European Commission has opened an online call for evidence on revising EU tobacco products and advertising rules, marking a new phase in the TPD/TAD review. Policy options may cover novel products, flavours, packaging, digital marketing and advertising. A 2Firsts review of 855 early submissions shows rapid engagement and recurring debate over differentiated regulation, harm reduction, youth protection, illicit trade and economic impact.
Special Report
May.21